On Aug. 9, 2023, reMind hosted a webinar with three psychedelic industry experts to discuss strategies and best practices of launching and operating a successful ketamine clinic, including establishing a mission, business plan, client care protocols, fundraising strategies, brand awareness, and location design. The panelists included: Kim Turpin, co-founder of the Pearl Psychedelic Institute; Nykol […]
Katherine MacLean is an accomplished research scientist who has studied the effects of psychedelics on cognitive performance, emotion wellbeing, spirituality, and brain function. As a post doctoral research fellow and faculty member at Johns Hopkins, she worked with Roland Griffiths on the groundbreaking clinical trials of psilocybin that were featured in Michael Pollan’s “How to […]
Derrick Knudsen is a founding partner of Meta Talent Group, a job-placement agency focused on the cannabis and psychedelics industries and strives to be “a bridge for growing companies and purpose-driven leaders who are seeking to improve the world socially and environmentally.” Earlier this year, Knudsen’s firm published its 2023 Psychedelic Salary Guide, which analyzes […]
Dr. Raymond Turpin is the clinical director for The Pearl Psychedelic Institute in Waynesville, North Carolina, and co-principal investigator of The Pearl MDMA Project. He has been studying the therapeutic uses of psychedelics and the relevant literature since the mid-1980s hoping to eventually legally use these medicines in his psychology practice. Dr. Turpin recently shared some […]
Tori Armbrust is founder of Satori Farms PDX, the first company to receive a license to manufacture psilocybin mushrooms in Oregon. A long-time mushroom enthusiast, cultivator, and educator, she is currently working with many of the new service centers opening under the rollout of Measure 109 by the Oregon Psilocybin Services Section. Armbrust recently shared […]
The underlying Bill, which had been previously endorsed in last year’s National Defense Authorization Act (NDAA), has encountered an obstacle during its journey as numerous progressive proposals hangs in the balance.
The purpose will be to “expand mental health treatment options in Massachusetts by providing new pathways to access natural psychedelic medicine therapy.”
The committee voted to advance the proposal, which would call on police to deprioritize enforcement of laws against all entheogenic substances, excluding peyote-derived mescaline.
A group of researchers point to a lack of “universally accepted protocols” for psilocybin-assisted therapy to treat depression.
Once in effect, these codes will allow physicians and other qualified health care professionals to seek coverage and reimbursement for providing psychedelic-assisted therapy, subject to approval by the U.S. Food and Drug Administration.
FDA’s draft guidance provides scientists with a framework to carry out research that could lead to the development of psychedelic medicines.
An analysis of key research published in the past month
The legislation heads to another committee before a chance for an Assembly-wide review—but the path to approval is “narrow”
And nearly half believe possession should be decriminalized for personal use for any reason.
Read Lucid News’ roundup of news from the conference.
The agency’s recommendations aim to inform psychedelic drug development.
Magic mushrooms help people process difficult emotions and feel more self-compassion, study suggests
Sen. Scott Wiener (D) said that while the reform legislation advanced through his chamber, “it’s not guaranteed to pass” in the Assembly.
The group’s thesis appears to fly in the face of a prominent tenet in some corners of psychedelic research that maintains it’s the 5-HT2A receptor primarily mediating the apparent therapeutic effects of psychedelics.
The legislation from Rep. Brandon Potter (D), which cleared a key committee last week, passed on the floor in a 54-11 vote on Monday, sending it to the Senate for consideration.
By exploring the binding traits of these chemicals, the researchers found they were able to separate the hallucinogenic properties.
The Funguyz chain of shroom shops plans to open two branches in less than three weeks.
Studying the effects of psychedelic therapy has many unique challenges.
While the first two psilocybin service centers to be licensed in Oregon under Measure 109 grabbed the headlines – EPIC Healing in Eugene and Inner Guidance Services in Albany – a very different vision for public access is about to unfold in Bend, Oregon